These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36629157)

  • 1. Clinical implications of endogenous testosterone density on prostate cancer progression in patients with very favorable low and intermediate risk treated with radical prostatectomy.
    Porcaro AB; Tafuri A; Panunzio A; Cerrato C; Bianchi A; Gallina S; Vidiri S; D'Aietti D; Serafin E; Mazzucato G; Princiotta A; Brusa D; Brunelli M; Pagliarulo V; Cerruto MA; Antonelli A
    Asian J Androl; 2023 Sep; 25(5):556-563. PubMed ID: 36629157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Influence of Endogenous Testosterone Density on Unfavorable Disease and Tumor Load at Final Pathology in Intermediate-Risk Prostate Cancer: Results in 338 Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection.
    Porcaro AB; Panunzio A; Tafuri A; Cerrato C; Gallina S; Bianchi A; Rizzetto R; Amigoni N; Gozzo A; Serafin E; Cianflone F; Migliorini F; Vidiri S; Di Filippo G; Novella G; Brunelli M; Shakir A; Pagliarulo V; Cerruto MA; Siracusano S; Antonelli A
    Urol Int; 2022; 106(9):928-939. PubMed ID: 35081537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive independent association between preoperative endogenous testosterone density and tumor load density in surgical specimen of patients undergoing radical prostatectomy.
    Porcaro AB; Bianchi A; Gallina S; Serafin E; Mazzucato G; Panunzio A; Tafuri A; Montanaro F; Marafioti Patuzzo G; Baielli A; Artoni F; Vidiri S; Cianflone F; D'Aietti D; Brunelli M; Siracusano S; Cerruto MA; Antonelli A
    Urologia; 2024 Feb; 91(1):76-84. PubMed ID: 37526101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous testosterone density predicts unfavorable disease at final pathology in intermediate risk prostate cancer.
    Porcaro AB; Tafuri A; Panunzio A; Rizzetto R; Amigoni N; Cerrato C; Shakir A; Gallina S; Bianchi A; Cianflone F; Serafin E; Gozzo A; Di Filippo G; Migliorini F; Novella G; Brunelli M; Cerruto MA; Antonelli A
    Int Urol Nephrol; 2021 Dec; 53(12):2517-2526. PubMed ID: 34580803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous testosterone density as ratio of endogenous testosterone levels on prostate volume predicts tumor upgrading in low-risk prostate cancer.
    Porcaro AB; Gallina S; Bianchi A; Cerrato C; Tafuri A; Rizzetto R; Amigoni N; Orlando R; Serafin E; Gozzo A; Migliorini F; Antoniolli SZ; Lacola V; De Marco V; Brunelli M; Cerruto MA; Siracusano S; Antonelli A
    Int Urol Nephrol; 2021 Dec; 53(12):2505-2515. PubMed ID: 34677784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor upgrading among very favorable intermediate-risk prostate cancer patients treated with robot-assisted radical prostatectomy: how can it impact the clinical course?
    Porcaro AB; Bianchi A; Panunzio A; Gallina S; Serafin E; Tafuri A; Trabacchin N; Orlando R; Ornaghi PI; Mazzucato G; Vidiri S; D'Aietti D; Montanaro F; Brusa D; Patuzzo GM; Artoni F; Baielli A; Migliorini F; De Marco V; Veccia A; Brunelli M; Siracusano S; Cerruto MA; Antonelli A
    Int Urol Nephrol; 2024 Aug; 56(8):2597-2605. PubMed ID: 38553619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous testosterone density is an independent predictor of pelvic lymph node invasion in high-risk prostate cancer: results in 201 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection.
    Porcaro AB; Tafuri A; Panunzio A; Mazzucato G; Cerrato C; Gallina S; Bianchi A; Rizzetto R; Amigoni N; Serafin E; Cianflone F; Orlando R; Gentile I; Migliorini F; Zecchini Antoniolli S; Di Filippo G; Brunelli M; Pagliarulo V; Cerruto MA; Antonelli A
    Int Urol Nephrol; 2022 Mar; 54(3):541-550. PubMed ID: 35044553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative endogenous testosterone density predicts disease progression from localized impalpable prostate cancer presenting with PSA levels elevated up to 10 ng/mL.
    Porcaro AB; Bianchi A; Mazzucato G; Gallina S; Serafin E; Tafuri A; Cerrato C; Panunzio A; Vidiri S; D'Aietti D; Orlando R; Brusa D; Brunelli M; Siracusano S; Cerruto MA; Antonelli A
    Int Urol Nephrol; 2023 Jan; 55(1):85-92. PubMed ID: 36197572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of prognostic group classification on prostate cancer progression in intermediate-risk patients according to the European Association of Urology system: results in 479 patients treated with robot-assisted radical prostatectomy at a single tertiary referral center.
    Porcaro AB; Bianchi A; Panunzio A; Gallina S; Tafuri A; Serafin E; Orlando R; Mazzucato G; Vidiri S; D'Aietti D; Montanaro F; Marafioti Patuzzo G; Artoni F; Baielli A; Ditonno F; Rizzetto R; Veccia A; Gozzo A; De Marco V; Brunelli M; Cerruto MA; Antonelli A
    Ther Adv Urol; 2024; 16():17562872241229260. PubMed ID: 38348129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative endogenous total testosterone predicts prostate cancer progression: results in 580 consecutive patients treated with robot assisted radical prostatectomy for clinically localized disease.
    Porcaro AB; Panunzio A; Serafin E; Bianchi A; Gallina S; Mazzucato G; Vidiri S; D'Aietti D; Orlando R; Ditonno F; Montanaro F; Marafioti Patuzzo G; Bailelli A; Artoni F; Zecchini Antoniolli S; Rizzetto R; Brunelli M; Siracusano S; Cerruto MA; Tafuri A; Antonelli A
    Int Urol Nephrol; 2023 May; 55(5):1139-1148. PubMed ID: 36943597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normal preoperative endogenous testosterone levels predict prostate cancer progression in elderly patients after radical prostatectomy.
    Porcaro AB; Panunzio A; Bianchi A; Cerrato C; Gallina S; Serafin E; Mazzucato G; Vidiri S; D'Aietti D; Orlando R; Brusa D; Brunelli M; Siracusano S; Pagliarulo V; Cerruto MA; Tafuri A; Antonelli A
    Ther Adv Urol; 2023; 15():17562872231154150. PubMed ID: 36846295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal total testosterone serum levels predict biopsy and pathological ISUP grade group in a large cohort of Caucasian prostate cancer patients who underwent radical prostatectomy.
    Tafuri A; Sebben M; Rizzetto R; Amigoni N; Shakir A; Processali T; Pirozzi M; Gozzo A; Odorizzi K; De Michele M; Gallina S; Bianchi A; Ornaghi PI; Brunelli M; Migliorini F; Cerruto MA; Siracusano S; Artibani W; Antonelli A; Porcaro AB
    Ther Adv Urol; 2020; 12():1756287220929481. PubMed ID: 32636934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance and risk factors of International Society of Urological Pathology (ISUP) grade upgrading in prostate cancer patients undergoing robot-assisted radical prostatectomy.
    Takeshima Y; Yamada Y; Teshima T; Fujimura T; Kakutani S; Hakozaki Y; Kimura N; Akiyama Y; Sato Y; Kawai T; Yamada D; Kume H
    BMC Cancer; 2021 May; 21(1):501. PubMed ID: 33947348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological factors associated with pathological upgrading from biopsy to prostatectomy in patients with ISUP grade group ≤2 prostate cancer.
    Li X; Wang ZX; Zhu YP; Wang J; Yin YS; Zeng XY
    Asian J Androl; 2022; 24(5):487-493. PubMed ID: 35170453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Impact and Clinical Implications of Adverse Tumor Grade in Very Favorable Low- and Intermediate-Risk Prostate Cancer Patients Treated with Robot-Assisted Radical Prostatectomy: Experience of a Single Tertiary Referral Center.
    Porcaro AB; Bianchi A; Gallina S; Panunzio A; Tafuri A; Serafin E; Orlando R; Mazzucato G; Ornaghi PI; Cianflone F; Montanaro F; Artoni F; Baielli A; Ditonno F; Migliorini F; Brunelli M; Siracusano S; Cerruto MA; Antonelli A
    Cancers (Basel); 2024 Jun; 16(11):. PubMed ID: 38893256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk and predictors of adverse pathology after radical prostatectomy in patients diagnosed with IUSP 1-2 prostate cancer at MRI-targeted biopsy: a multicenter analysis.
    Kesch C; Pantea V; Soeterik T; Marquis A; la Bombarda G; Morlacco A; Barletta F; Radtke JP; Darr C; Preisser F; Zattoni F; Marra G; van den Bergh RCN; Hadaschik B; Gandaglia G;
    World J Urol; 2023 Feb; 41(2):427-434. PubMed ID: 36534151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biparametric Prostate Imaging Reporting and Data System version2 and International Society of Urological Pathology Grade Predict Biochemical Recurrence after Radical Prostatectomy.
    Takeuchi N; Sakamoto S; Nishiyama A; Horikoshi T; Yamada Y; Iizuka J; Maimaiti M; Imamura Y; Kawamura K; Imamoto T; Komiya A; Ikehara Y; Akakura K; Ichikawa T
    Clin Genitourin Cancer; 2018 Aug; 16(4):e817-e829. PubMed ID: 29576444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Impact and Clinical Implications of Unfavorable Upgrading in Low-Risk Prostate Cancer after Robot-Assisted Radical Prostatectomy: Results of a Single Tertiary Referral Center.
    Porcaro AB; Panunzio A; Bianchi A; Sebben M; Gallina S; De Michele M; Orlando R; Serafin E; Mazzucato G; Vidiri S; D'Aietti D; Princiotta A; Montanaro F; Marafioti Patuzzo G; De Marco V; Brunelli M; Pagliarulo V; Cerruto MA; Tafuri A; Antonelli A
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
    Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
    BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Basal Total Testosterone Levels and Tumor Upgrading in Low and Intermediate Risk Prostate Cancer.
    Porcaro AB; De Luyk N; Corsi P; Sebben M; Tafuri A; Processali T; Cerasuolo M; Mattevi D; Cerruto MA; Brunelli M; Siracusano S; Artibani W
    Urol Int; 2017; 99(2):215-221. PubMed ID: 28245478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.